Anumana to Share Latest Advances in ECG-AI at AHA Scientific Sessions 2025

Company to present four studies, including a late-breaking featured science presentation, and host interactive experiences demonstrating AI’s role in cardiovascular care

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in AI-powered cardiovascular diagnostics, will present groundbreaking clinical studies demonstrating how AI applied to electrocardiograms (ECG) can uncover early signs of heart disease and inform clinical care. The company’s late-breaking featured science study, along with three additional accepted abstracts, will be presented at the American Heart Association (AHA) Scientific Sessions 2025, taking place November 7–10 in New Orleans, LA. Anumana will also host several interactive experiences for attendees to explore how AI can be seamlessly integrated into cardiovascular care.

“Together, the studies being presented at AHA continue to expand our growing body of evidence supporting the use of ECG-AI as an everyday clinical procedure,” said Simos Kedikoglou, MD, President and COO of Anumana. “Anumana’s software-as-a-medical-device is grounded in extensive training, retrospective validation, and prospective confirmation in more than 135,000 patients cumulatively. This robust foundation ensures that our AI platform is designed to deliver actionable insights for clinicians and improve patient outcomes.”

Abstract Presentations:

• Improved Identification of Near-Term Heart Failure Risk in Pooled Cohort Studies Using ECG-AI and PREVENT-HF (Late-Breaking Abstract) - November 8 at 3:15 p.m. CT (211-213)
• Is Parity an Independent Risk Factor for Takotsubo Cardiomyopathy (TTCM)? Using a Novel Research Platform with Large De-identified Electronic Health Record Data to Quantify Parity and its Association with TTCM - November 9 at 11:30 a.m. CT (Population Science Zone)
• Evaluation of a Novel Artificial Intelligence Electrocardiogram Tool for Early Identification of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension - November 10 at 9:22 a.m. CT (Clinical Science Zone 2‚ Moderated Digital Poster 22)
• A Multicenter Study of Detection of Pulmonary Hypertension Based on Point-of-Care 12-Lead ECG Data - November 10 at 9:36 a.m. CT (Clinical Science Zone 2‚ Moderated Digital Poster 22)

Engage with Anumana at AHA 2025—Booth #4719

Attendees are invited to connect with Anumana and experience the company’s AI-powered solutions firsthand:

• Interactive Booth Experience: Bring a photo of your 12-lead ECG to discover your “ECG AiGE™”—an informative, data-driven look at how old your ECG says your heart is.
• Evening Cocktail Event: AHA attendees can register to join Anumana for a networking reception on Saturday, November 8, at 6 p.m. local time, featuring brief presentations from Anumana’s leaders and nationally recognized experts in cardiac AI (click here for details).

Visit aha2025.anumana.ai for more information about Anumana at AHA.

About Anumana

Anumana is an AI-driven health technology company committed to transforming cardiovascular care. Co-founded by nference and Mayo Clinic, Anumana develops software-as-a-medical-device (SaMD) solutions that apply multimodal AI to support early detection, clinical decision-making, and intraoperative guidance across the continuum of care. The company’s portfolio includes ECG-based algorithms, generative imaging applications, and real-time procedural support tools designed to improve outcomes in both diagnostic and perioperative settings. The company’s FDA-cleared ECG-AI™ LEF algorithm is currently available in the U.S. and eligible for reimbursement as of January 2025. To learn more or schedule a demo, visit ECG-AI LEF. Please visit www.anumana.ai for more information and follow Anumana on LinkedIn and X for company updates.

Media Contact
Andrea Sampson
President/CEO, Sampson Public Relations Group
asampson@sampsonprgroup.com